{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-042938","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.693687+00:00","generated_at":"2026-06-02T00:43:39.400685+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroOne Q2 FY2024 product revenue triples to $1.38M; OneRF ablation system launched","bullets":["Product revenue $1.38M in Q2 2024, up from $466K in Q2 2023.","Net loss narrowed to $2.9M vs $3.5M a year ago; six-month net loss $6.2M.","Cash and cash equivalents $2.4M as of March 31, 2024, down from $5.3M at Sept 30, 2023.","Initiated limited commercial launch of OneRF Ablation System in late March; 5 patients implanted.","Zimmer Biomet continued expanding sEEG electrode accounts; raised $2.0M via ATM in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-042938","json":"https://secwatch.observer/filing/0001213900-24-042938.json","markdown":"https://secwatch.observer/filing/0001213900-24-042938.md","text":"https://secwatch.observer/filing/0001213900-24-042938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024042938/0001213900-24-042938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024042938/ea0205728-8k_neuro.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:43:39.400685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12e72465354dc765a94d1df578a23a826b1317b7","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp reported second quarter fiscal year 2024 ended March 31, 2024 results: revenue $1,377,000, net income $2.9 million.","evidence_excerpt":"results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: ● Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023 ● Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo ® sEEG: ● Zimmer Biomet continued to expand into new","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024042938/0001213900-24-042938-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter fiscal year 2024 ended March 31, 2024"},{"label":"Revenue","value":"$1,377,000"},{"label":"Net income","value":"$2.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}